Current Breast Cancer Reports

, Volume 4, Issue 4, pp 257–263

Treatment of Bone Metastases in Breast Cancer: an Update

Translational Research (V Stearns, Section Editor)

DOI: 10.1007/s12609-012-0089-1

Cite this article as:
Barginear, M.F. & Van Poznak, C.H. Curr Breast Cancer Rep (2012) 4: 257. doi:10.1007/s12609-012-0089-1


Bone is the most common site of breast cancer metastases. When breast cancer has metastasized to bone, it is considered an incurable disease. Osseous metastases are associated with significant morbidities including pain, pathological fractures, hypercalcemia of malignancy, and spinal cord compression. In this setting, the palliative goals of care include preventing skeletal related events, managing complications, reducing bone pain, and improving quality of life. Antiresorptive agents such as bisphosphonates have been the mainstay of bone-directed treatment, along with radiation therapy, and surgery. Most recently, RANKL-inhibitors have become another tool in the treatment of bone metastases. This review discusses bone-modifying agents and other targeted interventions in breast cancer patients with skeletal metastases.


Breast cancer Bone metastases Skeletal metastases Skeletal related events SREs Antiresorptive agents Bisphosphonates Denosumab Bone modifying agents Surgery Radiation therapy Radiopharmaceuticals Interventions Treatment Monitoring Imaging Bone turnover markers 

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Monter Cancer Center of the North Shore–LIJ Cancer InstituteHofstra North Shore–LIJ School of MedicineLake SuccessUSA
  2. 2.University of Michigan Comprehensive Cancer CenterAnn ArborUSA

Personalised recommendations